

COMPANY ACHIEVEMENTS 2018 YEAR TO DATE

June 2018

4Dx has achieved a number of significant milestones during the first half of 2018.

Investor Relations

Following continued strong interest in the Series B capital round after it was fully subscribed in March (\$5M), the 4Dx board extended the round to \$10M and continues to receive strong investor interest.



Regulatory Clearance

2018 has seen significant progress in 4Dx obtaining regulatory clearance for its first product in the USA, namely:

- 4Dx submitted its FDA 510(k) regulatory pre-submission in January.
- 4Dx met with the FDA in March in order to receive feedback on the pre-submission. As standard practice following the meeting, 4Dx submitted meeting minutes to the FDA outlining our understanding of discussions at the meeting.
- In April, the FDA has reviewed and accepted these minutes to the official administrative record. Importantly, the two outcomes clarified in the minutes were that 4Dx has a 510(k) pathway to FDA clearance with a viable predicate device, and how 4Dx can successfully gain clearance with a relatively modest sized clinical study.



4Dx Hardware & Software Revenue

In May, a second major USA hospital has received a grant award of US \$600,000 from the United States National Institutes of Health for the purchase of a 4Dx preclinical lung scanner. The hospital is now in negotiations with 4Dx to extend the SaaS contract a further 4 years (to 5 years of SaaS in total).

In June, the Australian National Imaging Facility is establishing a 4Dx technology translational research eco-system in Adelaide with a commitment in excess of \$1M of 4Dx software and hardware. The technology is being used for research on mice, sheep, pigs and in clinical research studies and represents significant endorsement from the local scientific community and unique opportunity for Australian researchers to leverage 4Dx technology.

Based on early commercial successes in the first half of this year, 4Dx management is extremely confident the company will achieve its revenue forecast for CY 2018.

International Marketing

4Dx attended this year's ATS Conference held May 18-23 in San Diego. ATS represented a unique opportunity to launch 4Dx Group brands to industry and communicate our value proposition to Physicians and Researchers. It also facilitated dialogue with the pharmaceutical industry. Core conference objectives were to solicit interest in Top 50 hospitals to collaborate with 4Dx.

The trade show exceeded all expectations:

- Strong engagement from visitors with quality collaboration interest shown from targeted organisations
- ATS ranked 4Dx stand in top 4% of all exhibitors (# 3 in our category)
- 420 individual 4Dx leads captured (researchers or clinicians from targeted organisations)
- 14 x collaborator/KOL 1:1 meetings conducted at the stand
- Requests from a number of "Top 50" organisations to collaborate with 4Dx



Clinical Collaborations

Following ATS, 4Dx is on track to reach its target of having working collaborations with 10 of the Top 50 hospitals/ research institutions by December 2018.

4Dx currently has active collaborations / commitments with:

- Cedars Sinai – Scanner and Clinical Trial underway
- Harvard/MGH – Clinical trial commitment
- Cleveland Clinic – Scanner and Clinical Trial commitment
- Children's LA – Collaboration agreement
- USC (Keck School of Medicine) – Collaboration commitment
- Australian National Imaging Facility – Research eco-system
- Telethon Kids Institute (Perth) – Collaboration commitment
- American Lung Transplant Association – Collaboration commitment

4Dx is currently scoping up potential collaborations with:


- Johns Hopkins – Collaboration agreement (including Preclinical Scanner)
- University of Alabama – Clinical trial participation
- National Jewish Health – Collaboration agreement
- Veterans Affairs – Clinical trial participation
- Royal Brompton – Collaboration agreement

4Dx is also in dialogue with a number of pharmaceutical companies on how 4Dx technology can support their preclinical and clinical trial programs.

Other Developments

Other significant develops in 2018 included:

- UL certification of the Preclinical scanner and first customer delivery
- Negotiating the transfer of 4Dx hardware manufacturing & support to a global hardware OEM



- Development of a 3rd party leasing arrangements for 4Dx hardware and software bundled solutions
- The signing of a term sheet for the development of a 4Dx equine scanner